Gapping down
In reaction to earnings/guidance:
- FAST -5.5%, DAL -3.7%
Other news:
- HGEN -65.2% (receives preliminary topline data from NIH/NIAID study of Lenzilumab in ACTIV-5/BET-B ; study did not meet primary endpoint)
- ATRA -50.9% (completes ATA188 Phase 2 EMBOLD Study interim analysis)
- U -7.1% (Unity (U) confirms merger agreement with ironSource)
- FAST -5.2% (authorizes new 8 mln share repurchase program)
- CRNT -3.7% (AVNW issues letter to CRNT shareholders re acquisition proposal)
- SLI -3.2% (provides updates on project developments)
- ILMN -2.1% (loses Grail antitrust probe challenge against EU according to Reuters)
- KNTK -1.3% (files for $400 mln mixed securities shelf offering)
- DM -1.2% (CFO resigning to pursue other interests)
Analyst comments:
- CWAN -5% (downgraded to Sell from Neutral at Goldman)
- AZEK -4% (downgraded to Buy from Conviction Buy at Goldman)
- CZR -1% (downgraded to Sector Weight from Overweight at KeyBanc Capital Markets)